Cargando…

Diagnostic and Therapeutic Pathways of Intramuscular Myxoma

Intramuscular myxomas (IMMs) are benign tumors. Evidence regarding diagnostic and therapeutic pathways is rare, and guidelines do not exist due to their low incidence. The aim of this study was a retrospective analysis at a university cancer center and the interdisciplinary re-evaluation of the indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Reiter, Alonja, Trumm, Katharina, Ballhause, Tobias M., Weiss, Sebastian, Frosch, Karl-Heinz, Korthaus, Alexander, Bechler, Ulrich, Duprée, Anna, Luebke, Andreas, Bannas, Peter, Schlickewei, Carsten W., Priemel, Matthias H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316518/
https://www.ncbi.nlm.nih.gov/pubmed/35885479
http://dx.doi.org/10.3390/diagnostics12071573
_version_ 1784754834119852032
author Reiter, Alonja
Trumm, Katharina
Ballhause, Tobias M.
Weiss, Sebastian
Frosch, Karl-Heinz
Korthaus, Alexander
Bechler, Ulrich
Duprée, Anna
Luebke, Andreas
Bannas, Peter
Schlickewei, Carsten W.
Priemel, Matthias H.
author_facet Reiter, Alonja
Trumm, Katharina
Ballhause, Tobias M.
Weiss, Sebastian
Frosch, Karl-Heinz
Korthaus, Alexander
Bechler, Ulrich
Duprée, Anna
Luebke, Andreas
Bannas, Peter
Schlickewei, Carsten W.
Priemel, Matthias H.
author_sort Reiter, Alonja
collection PubMed
description Intramuscular myxomas (IMMs) are benign tumors. Evidence regarding diagnostic and therapeutic pathways is rare, and guidelines do not exist due to their low incidence. The aim of this study was a retrospective analysis at a university cancer center and the interdisciplinary re-evaluation of the individual diagnostic and therapeutic procedures. Overall, 38 patients were included in the study. IMMs occurred mostly in middle-aged women. At the time of first consultation, 57.9% had few symptoms or were asymptomatic. In 92.1% of the cases, the tumor was localized in the extremities. The lower extremity was affected in 73.7%. The average size of IMMs was 5.0 cm. The proximally located tumors in the gluteus, thighs, and upper arms were significantly larger (p = 0.02) than the distally-located tumors in the forearms and lower legs. An MRI was performed in 97.4%. Based on imaging, an IMM was suspected in 5.6% by radiologists and in 54.1% by musculoskeletal surgeons. An incision biopsy was performed in 68.4% and led in 100.0% to the right histopathological diagnosis. In total, 89.5% of IMMs were resected. Postoperative complications requiring revision occurred in 8.8%. Recurrences or degenerations of IMMs were not reported in any of these cases.
format Online
Article
Text
id pubmed-9316518
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93165182022-07-27 Diagnostic and Therapeutic Pathways of Intramuscular Myxoma Reiter, Alonja Trumm, Katharina Ballhause, Tobias M. Weiss, Sebastian Frosch, Karl-Heinz Korthaus, Alexander Bechler, Ulrich Duprée, Anna Luebke, Andreas Bannas, Peter Schlickewei, Carsten W. Priemel, Matthias H. Diagnostics (Basel) Article Intramuscular myxomas (IMMs) are benign tumors. Evidence regarding diagnostic and therapeutic pathways is rare, and guidelines do not exist due to their low incidence. The aim of this study was a retrospective analysis at a university cancer center and the interdisciplinary re-evaluation of the individual diagnostic and therapeutic procedures. Overall, 38 patients were included in the study. IMMs occurred mostly in middle-aged women. At the time of first consultation, 57.9% had few symptoms or were asymptomatic. In 92.1% of the cases, the tumor was localized in the extremities. The lower extremity was affected in 73.7%. The average size of IMMs was 5.0 cm. The proximally located tumors in the gluteus, thighs, and upper arms were significantly larger (p = 0.02) than the distally-located tumors in the forearms and lower legs. An MRI was performed in 97.4%. Based on imaging, an IMM was suspected in 5.6% by radiologists and in 54.1% by musculoskeletal surgeons. An incision biopsy was performed in 68.4% and led in 100.0% to the right histopathological diagnosis. In total, 89.5% of IMMs were resected. Postoperative complications requiring revision occurred in 8.8%. Recurrences or degenerations of IMMs were not reported in any of these cases. MDPI 2022-06-28 /pmc/articles/PMC9316518/ /pubmed/35885479 http://dx.doi.org/10.3390/diagnostics12071573 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Reiter, Alonja
Trumm, Katharina
Ballhause, Tobias M.
Weiss, Sebastian
Frosch, Karl-Heinz
Korthaus, Alexander
Bechler, Ulrich
Duprée, Anna
Luebke, Andreas
Bannas, Peter
Schlickewei, Carsten W.
Priemel, Matthias H.
Diagnostic and Therapeutic Pathways of Intramuscular Myxoma
title Diagnostic and Therapeutic Pathways of Intramuscular Myxoma
title_full Diagnostic and Therapeutic Pathways of Intramuscular Myxoma
title_fullStr Diagnostic and Therapeutic Pathways of Intramuscular Myxoma
title_full_unstemmed Diagnostic and Therapeutic Pathways of Intramuscular Myxoma
title_short Diagnostic and Therapeutic Pathways of Intramuscular Myxoma
title_sort diagnostic and therapeutic pathways of intramuscular myxoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316518/
https://www.ncbi.nlm.nih.gov/pubmed/35885479
http://dx.doi.org/10.3390/diagnostics12071573
work_keys_str_mv AT reiteralonja diagnosticandtherapeuticpathwaysofintramuscularmyxoma
AT trummkatharina diagnosticandtherapeuticpathwaysofintramuscularmyxoma
AT ballhausetobiasm diagnosticandtherapeuticpathwaysofintramuscularmyxoma
AT weisssebastian diagnosticandtherapeuticpathwaysofintramuscularmyxoma
AT froschkarlheinz diagnosticandtherapeuticpathwaysofintramuscularmyxoma
AT korthausalexander diagnosticandtherapeuticpathwaysofintramuscularmyxoma
AT bechlerulrich diagnosticandtherapeuticpathwaysofintramuscularmyxoma
AT dupreeanna diagnosticandtherapeuticpathwaysofintramuscularmyxoma
AT luebkeandreas diagnosticandtherapeuticpathwaysofintramuscularmyxoma
AT bannaspeter diagnosticandtherapeuticpathwaysofintramuscularmyxoma
AT schlickeweicarstenw diagnosticandtherapeuticpathwaysofintramuscularmyxoma
AT priemelmatthiash diagnosticandtherapeuticpathwaysofintramuscularmyxoma